- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01261923
Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease
Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients
Study Overview
Detailed Description
This study aims to investigate whether liver patients may tolerate alitretinoin.
Toctino (alitretinoin) is a vitamin A like substance that has proven effective in the treatment of specially hand eczema. The medicine is taken as capsules daily for up to 3 months. Toctino is currently only approved for patients with normal liver function, because it has never been studied how drug metabolism and excretion occurs in liver disease patients. This, however, the investigators want to examine in order to achieve an additional treatment for patients with severe hand eczema and concomitant liver disease.
The study is a collaboration between dermatology and medical department, Gentofte Hospital and University of Copenhagen, where blood and urine tests will be conducted. From the medical department, 8 patients diagnosed with liver disease will be recruited. Patients should only receive a single dose of Toctino (30 mg capsules). 20 blood samples and one urine sample will be taken over the next 24 hours (approximately 250-300 ml) to measure the concentration of Toctino in blood and urine. Moreover, the urine will be collected over 24 hours. Then the investigators will recruit an 8-person control group that is matched according to gender, age and weight. In this control group will take exactly the same samples. Based on determining concentrations in blood and urine will be able to mathematically calculate how Toctino is absorbed, distributed and excreted in liver disease patients in conjunction with a healthy control group. The study will therefore help to determine what dose of Toctino that would be preferable in liver disease patients.
The survey is estimated to be associated with a very low risk both for participating patients and control group. Toctino is an approved drug and side effects occur almost exclusively in long term treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Hellerup, Denmark, 2900
- Gentofte Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be medically stable for at least 1 month before the intake of 9-cis-RA.
- There must be an ultrasound scan of liver and abdomen within the last 3 months (liver size, ascites).
- In women of childbearing age, there must be a negative pregnancy test, while that to be used adequate contraception (the pill, coil or surgical sterilization) at least 1 month after taking the study medication.
Exclusion Criteria:
- Clinically significant deviations in routine blood tests (hematology, electrolytes and kid-ney, urinalysis). Differences attributable to underlying liver disease are excluded.
- Encephalopathy (> grade II)
- Concomitant treatment with drugs predominantly metabolised in the liver by CYP3A4.
- Clinically significant ECG changes, cardiovascular disease and AMI within the last 12 months
- Affected renal function judged by Cockcroft-Gault formula.
- Epilepsy or significant neurological disease that requires drug therapy.
- History of cerebrovascular relapse
- Esophagus bleeding
- Severe ascites
- HIV
- Mental illness.
- Active cancer
- Pregnancy or pregnancy plan within 3 months.
- Breastfeeding women.
- Participation in other clinical projects.
- Intake of clinical trial medication in the past month.
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alitretinoin - Hepatic Insufficiency
metabolism of 30 mg alitretinoin single dose in 8 patients with Hepatic Insufficiency
|
30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
Other Names:
|
Experimental: Alitretinoin - Hepatic Insufficiency Controls
metabolism of 30 mg alitretinoin single dose in 8 healthy controls.
|
30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The investigators wish to investigate whether the metabolism of alitretinoin differs between healthy controls and patients with moderate to severe hepatic disease
Time Frame: 2 years
|
The metabolism of alitretinoin will be examined by measuring blood concentrations after time: 0 , ¼, ½, ¾, 1, 1¼, 1½, 2, 2½, 3, 3½, 4, 5, 6, 8, 10, 12 and 24 hours.
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Frederik Grønhøj, MD DMSci, Gentofte Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Eudra CT 2010-020212-11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Insufficiency
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
BeiGeneCompletedHepatic Insufficiency & Healthy SubjectsUnited States
-
BayerCompletedHepatic Insufficiency, Renal InsufficiencyGermany, Romania
-
Cardiox CorporationTerminatedHepatic Failure
-
Novartis PharmaceuticalsCompletedHepatic FailureUnited States
-
Centre Hospitalier Universitaire de NiceCompleted
-
Biotie Therapies Inc.Acorda TherapeuticsTerminatedHepatic ImpairmentUnited States
-
PfizerMedivation, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisUnknownFulminating Hepatic FailureFrance
-
National Taiwan University HospitalUnknownLiver Failure | Critical CareTaiwan
Clinical Trials on Alitretinoin
-
Basilea PharmaceuticaCompletedHand DermatosesPoland, Germany, Canada
-
Stiefel, a GSK CompanyBasilea PharmaceuticaCompleted
-
University Hospital MuensterBasilea Pharmaceutica International LtdTerminatedLupus Erythematosus, CutaneousGermany
-
Basilea PharmaceuticaCompletedHand DermatosesGermany
-
Basilea PharmaceuticaCompleted
-
Basilea PharmaceuticaCompletedHand DermatosesGermany
-
University of ZurichUnknown
-
Stiefel, a GSK CompanyBasilea PharmaceuticaCompletedPsoriasisFrance, Germany, United Kingdom, Netherlands
-
Anderson Clinical ResearchLigand PharmaceuticalsCompletedHIV Infections | Sarcoma, Kaposi
-
Anderson Clinical ResearchLigand PharmaceuticalsCompletedHIV Infections | Sarcoma, Kaposi